Rachel V Thomas

Health and Me

GLP-1 Drugs May Offer Mental Health Benefits, Reduce Schizophrenia Relapses: Lancet Study

GLP-1 Drugs May Offer Mental Health Benefits, Cut Schizophrenia Relapses: Lancet Study

Beyond weight loss and <span><a href="https://www.healthandme.com/health/diabetes">diabetes</a></span> control, GLP-1 drugs may offer mental health benefits by reducing the need for psychiatric hospital care among people with <span><a href="https://www.healthandme.com/health/schizophrenia">schizophrenia</a></span> and type 2 diabetes (T2D), according to a new study published in The Lancet Psychiatry.

The findings showed that treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) was associated with lower risks of psychiatric hospitalization and emergency department visits among people with both conditions.

Researchers from Deakin University and the University of Queensland in Australia analyzed US health records of more than 70,000 adults with schizophrenia and T2D who received treatment between January 2018 and October 2026.

The researchers found that people taking GLP-1 drugs were:

<ul><li>24% less likely to require psychiatric hospitalization than those not taking any of the compared diabetes medications.</li><li>18% less likely to require psychiatric hospitalization than those taking DPP-4 inhibitors.</li><li>17% less likely to require psychiatric hospitalization than those taking SGLT2 inhibitors.</li></ul>

GLP-1 use was also associated with fewer psychiatric emergency department visits. Compared with the same groups, users were:

<ul><li>29% less likely to require emergency care than those not taking any of the compared diabetes medications.</li><li>13% less likely than those taking DPP-4 inhibitors.</li><li>20% less likely than those taking SGLT2 inhibitors.</li></ul>The association between GLP-1 treatment and lower use of acute psychiatric care was strongest among people who lost weight. However, it was also observed, to a lesser extent, among those whose weight remained stable or increased. This suggests that weight loss alone may not explain the association.

Further, when the researchers analyzed individual drugs, the association was observed with <span>semaglutide</span>, liraglutide, and tirzepatide, but not dulaglutide. 

<h2>GLP-1 Drugs Not Primary Treatment for Schizophrenia</h2>

The researchers cautioned that the observational study cannot establish that GLP-1 drugs directly reduce the need for acute psychiatric care.

They said the medications should not be considered primary psychiatric treatments or prescribed solely to reduce psychiatric hospitalizations and emergency visits.

Instead, the findings point to a potential additional benefit when GLP-1 drugs are prescribed for appropriate metabolic indications as part of integrated cardiometabolic and mental health care.

“The findings suggest that lower psychiatric acute-care use could be a favourable secondary benefit when GLP-1-based therapies are clinically indicated for metabolic management,” the researchers said.

They added that randomized clinical trials and mechanistic studies are needed to determine whether the drugs have a direct effect on psychiatric outcomes. Further research should also investigate their potential benefits in people with schizophrenia who do not have T2D.

<h2>Why Is Type 2 Diabetes More Common in People With Schizophrenia?</h2>

Schizophrenia is a serious psychiatric disorder associated with disability, other health conditions, and premature mortality. Cardiometabolic diseases, including T2D, contribute substantially to this burden.

Studies suggest that diabetes may be up to five times more common among people with schizophrenia than among those without the condition. Approximately one in five people with schizophrenia may also have diabetes.

Several factors may contribute to this increased risk, including:

<ul><li>Obesity</li><li>High cholesterol and other abnormal blood lipid levels</li><li>Elevated blood sugar</li><li>Smoking</li><li>Unhealthy diet</li><li>Physical inactivity</li><li>Poor sleep</li><li>Stress</li></ul>Antipsychotic medications can also contribute to metabolic problems, including weight gain, insulin resistance, and abnormal blood lipid levels. These adverse effects may affect treatment adherence and complicate the management of schizophrenia.

<h2>Could GLP-1 Drugs Help Address Both Conditions?</h2>

GLP-1 receptor agonists are an established class of medications used to manage T2D and, in some cases, obesity. Their potential role in people with schizophrenia is of growing interest because of the high burden of metabolic disease in this population.

However, whether these medications directly improve psychiatric outcomes remains uncertain.

The latest findings suggest that GLP-1 treatment may be associated with reduced use of acute psychiatric care among people with schizophrenia and T2D. Further clinical trials are needed before any direct mental health benefit can be established.

Health Conditions A-Z

health

glp-1-drugs-may-offer-mental-health-benefits-cut-schizophrenia-relapses-lancet-study

glp 1 drugs

glp 1 Mental Health

schizophrenia

Schizophrenia diabetes

diabetes

glp 1 diabetes

semaglutide

glp 1

burning-skin-panic-attack-depression-godzilla-weight-loss-drug-retatrutide-linked-to-129-symptoms

Burning Skin, Panic Attack & Depression: ‘Godzilla’ Weight Loss Drug Retatrutide Linked To 129 Symptoms

sky-turns-orange-in-indonesia-how-toxic-smog-from-wildfires-can-impact-health

Sky Turns Orange In Indonesia: How Toxic Smog From Wildfires Can Impact Health

Health & Wellness

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Beyond weight loss and diabetes control, GLP-1 drugs may offer mental health benefits by reducing the need for psychiatric hospital care among people with schizophrenia and type 2 diabetes (T2D), according to a new study published in The Lancet Psychiatry.The findings showed that treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) was associated with lower risks of psychiatric hospitalization and emergency department visits among people with both conditions.What Did the Study Find?Researchers from Deakin University and the University of Queensland in Australia analyzed US health records of more than 70,000 adults with schizophrenia and T2D who received treatment between January 2018 and October 2026.The researchers found that people taking GLP-1 drugs were:24% less likely to require psychiatric hospitalization than those not taking any of the compared diabetes medications.18% less likely to require psychiatric hospitalization than those taking DPP-4 inhibitors.17% less likely to require psychiatric hospitalization than those taking SGLT2 inhibitors.GLP-1 use was also associated with fewer psychiatric emergency department visits. Compared with the same groups, users were:29% less likely to require emergency care than those not taking any of the compared diabetes medications.13% less likely than those taking DPP-4 inhibitors.20% less likely than those taking SGLT2 inhibitors.The association between GLP-1 treatment and lower use of acute psychiatric care was strongest among people who lost weight. However, it was also observed, to a lesser extent, among those whose weight remained stable or increased. This suggests that weight loss alone may not explain the association.Further, when the researchers analyzed individual drugs, the association was observed with semaglutide, liraglutide, and tirzepatide, but not dulaglutide. GLP-1 Drugs Not Primary Treatment for SchizophreniaThe researchers cautioned that the observational study cannot establish that GLP-1 drugs directly reduce the need for acute psychiatric care.They said the medications should not be considered primary psychiatric treatments or prescribed solely to reduce psychiatric hospitalizations and emergency visits.Instead, the findings point to a potential additional benefit when GLP-1 drugs are prescribed for appropriate metabolic indications as part of integrated cardiometabolic and mental health care.“The findings suggest that lower psychiatric acute-care use could be a favourable secondary benefit when GLP-1-based therapies are clinically indicated for metabolic management,” the researchers said.They added that randomized clinical trials and mechanistic studies are needed to determine whether the drugs have a direct effect on psychiatric outcomes. Further research should also investigate their potential benefits in people with schizophrenia who do not have T2D.Why Is Type 2 Diabetes More Common in People With Schizophrenia?Schizophrenia is a serious psychiatric disorder associated with disability, other health conditions, and premature mortality. Cardiometabolic diseases, including T2D, contribute substantially to this burden.Studies suggest that diabetes may be up to five times more common among people with schizophrenia than among those without the condition. Approximately one in five people with schizophrenia may also have diabetes.Several factors may contribute to this increased risk, including:ObesityHigh cholesterol and other abnormal blood lipid levelsElevated blood sugarSmokingUnhealthy dietPhysical inactivityPoor sleepStressAntipsychotic medications can also contribute to metabolic problems, including weight gain, insulin resistance, and abnormal blood lipid levels. These adverse effects may affect treatment adherence and complicate the management of schizophrenia.Could GLP-1 Drugs Help Address Both Conditions?GLP-1 receptor agonists are an established class of medications used to manage T2D and, in some cases, obesity. Their potential role in people with schizophrenia is of growing interest because of the high burden of metabolic disease in this population.However, whether these medications directly improve psychiatric outcomes remains uncertain.The latest findings suggest that GLP-1 treatment may be associated with reduced use of acute psychiatric care among people with schizophrenia and T2D. Further clinical trials are needed before any direct mental health benefit can be established.